title: Cost-effective treatment of acute coronary syndromes-IIB or not IIB?
authors.forename: W W
authors.initials: WW
authors.lastname: Klein
mesh_terms: D000789:Angina, Unstable / Q000188:drug therapy / Q000191:economics*; D003362:Cost-Benefit Analysis; D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy / Q000191:economics*; D010975:Platelet Aggregation Inhibitors / Q000191:economics* / Q000627:therapeutic use; D012189:Retrospective Studies; D013557:Switzerland; D000077466:Tirofiban; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use
chemical_list: D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D014443:Tyrosine; D006493:Heparin; D000077466:Tirofiban